Press Releases

InVivo Therapeutics Featured on CBS Radio Affiliate

Published: May 26, 2016

- Industry Veteran Jeff Brown Interviews CEO and Chairman Mark Perrin on WBZ NewsRadio 1030 in Boston – CAMBRIDGE, Mass. (May 26, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company was featured in a WBZ NewsRadio 1030 (CBS – Boston) interview with New England Business reporter Jeff Brown. Mr. Brown has been with WBZ NewsRadio since 2012 and is a 30-year veteran of the broadcast industry.  The interview aired a number of times on May 23 and May 24 with a total audience reach of nearly a half million listeners. “It was a pleasure to share details […]

View Article
InVivo Therapeutics Announces Notice of Allowance for Patent Covering Methods of Treating Spinal Cord Injuries Using a Broad Array of Polymeric Implants, Including the Neuro-Spinal Scaffold™

Published: May 18, 2016

CAMBRIDGE, Mass. (May 18, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a Notice of Allowance has been received from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/694,466, titled “Methods and Compositions for the Treatment of Open and Closed Wound Spinal Cord Injuries”. The application covers methods of treatment of compression or contusion spinal cord injuries with a broad array of biodegradable and/or bioabsorbable polymeric implants that includes InVivo’s Neuro-Spinal Scaffold™, which is currently being studied in the pivotal INSPIRE study. Of note, the allowed claims cover methods of use for a broader spectrum of polymeric compositions than claims […]

View Article
InVivo Therapeutics Announces Hospital of the University of Pennsylvania as New Site for INSPIRE Study

Published: May 11, 2016

CAMBRIDGE, Mass. (May 11, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the Hospital of the University of Pennsylvania (HUP), a part of the University of Pennsylvania Health System in Philadelphia, PA, has been added as a clinical site for The INSPIRE Study. “Penn Medicine has a longstanding tradition of making medical advancements that have helped to mold the standard of care. InVivo’s innovative therapeutic approach holds promise and we look forward to being a part of the study,” said James Schuster, M.D., Ph.D., Associate Professor of Neurosurgery, Associate Director of the Neurocritical Care-Trauma, and Principal Investigator at the […]

View Article
InVivo Therapeutics Reports 2016 First Quarter Financial Results and Business Update

Published: May 6, 2016

CAMBRIDGE, Mass. (May 6, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the quarter ended March 31, 2016. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “In the first quarter, we reached significant milestones that have clarified our path to commercialization and increased the likelihood of approval for the Neuro-Spinal Scaffold™ for acute thoracic spinal cord injury. We established a measure of success for the INSPIRE study when we received approval for an amendment that defined the Objective Performance Criterion (OPC) as 25% or more of the patients in the study demonstrating an improvement of […]

View Article
InVivo Therapeutics Announces Symposium at 84th American Association for Neurological Surgeons Annual Scientific Meeting

Published: May 2, 2016

- Symposium to Feature Drs. Robert Langer, Domagoj Coric, and James Guest – CAMBRIDGE, Mass. (May 2, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be holding a symposium at the 84th American Association for Neurological Surgeons (AANS) Annual Scientific Meeting on Monday, May 2, 2016 in Chicago, IL. InVivo will have several other engagement opportunities, including a Steering Committee meeting and an exhibitor booth. The symposium presentation is titled “Innovation in Spinal Cord Injury Treatment: The Investigational Neuro-Spinal Scaffold™ and Bioengineered Neural Trails™” and will feature presentations by three renowned key opinion leaders: Robert Langer, Sc.D., the David H. […]

View Article
InVivo Therapeutics Reports Conversion of a Fourth Patient Implanted with the Neuro-Spinal Scaffold™ in the INSPIRE Study

Published: April 26, 2016

- Four Out of First Six Patients Have Converted from Complete to Incomplete Spinal Cord Injury – CAMBRIDGE, Mass. (Apr 26, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the sixth-implanted patient in the INSPIRE study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the fourth out of the first six patients (67%) with at least two months of follow up data to have had an AIS grade improvement. The Objective Performance Criterion (OPC), a measure of study success for the INSPIRE study, is defined as […]

View Article
InVivo Therapeutics to Present at Committee Roundtable on Biomedical Engineering Materials and Applications

Published: April 20, 2016

CAMBRIDGE, Mass. (April 20, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Thomas Ulich, M.D., Chief Scientific Officer, is scheduled to present at the Committee Roundtable on Biomedical Engineering Materials and Applications (BEMA) to be held on Monday, April 25, 2016 in Washington, D.C. The topic of the session is “Neuro Devices and Neuro Regeneration”. Dr. Ulich said, “We are looking forward to communicating InVivo’s program in the use of preformed and injectable scaffolds for the therapy of acute and chronic spinal cord injury.” BEMA is a roundtable initiative of the National Research Council of the National Academies […]

View Article
InVivo Therapeutics Expresses Condolences on Death of Eighth Patient Enrolled in INSPIRE Study

Published: April 19, 2016

- New Patient Enrolled in Study Died From Underlying Injuries – CAMBRIDGE, Mass. (Apr 19, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that an eighth patient enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) has died after injuries from a severe motor vehicle accident and unrelated to the investigational product. Travis Dumont, M.D., Director of the Neurovascular Program and Principal Investigator at Banner University Medical Center – Tucson performed the implantation on April 12, 2016, approximately 71 hours after the injury occurred. […]

View Article
InVivo Therapeutics Announces John A. McCarthy, Jr. to Not Stand for Re-election

Published: April 12, 2016

- Company Thanks for His Service – CAMBRIDGE, Mass. (April 12, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that John A. McCarthy, Jr. has decided not to stand for re-election to the Board of Directors at the Company’s 2016 Annual Meeting of the Stockholders. Mr. McCarthy is departing to devote more time to his role as Chief Executive Officer and a director of ZS Genetics, Inc. as well as his other business ventures. Mr. McCarthy will continue to serve as a director of the Company until the expiration of his term at the conclusion of the Company’s 2016 […]

View Article
InVivo Therapeutics Announces University of Virginia Health System as New Site for INSPIRE Study

Published: April 5, 2016

CAMBRIDGE, Mass. (April 5, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of Virginia (UVA) Health System in Charlottesville, VA has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The UVA Health System serves a large geographic area with a population base of approximately 800,000 in central Virginia and receives transfers from the rest of the state. “Spinal cord injury is a devastating condition with severe personal and societal costs. We are excited to participate in […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.